Nutraceutical treatments for hypercholesterolemia in dialysis patients
Further confirmation of Medronys cholesterol® efficacy from latest clinical study conducted on elderly patients with chronic renal failure on dialysis and suffering from hypercholesterolemia
The study, published in the scientific review “International Journal of Medical and Nursing Approach (IJMNA)”, evaluated the efficacy of Medronys Colesterolo® on the lipid profile and in particular on the value of HDL cholesterol in patients with CRI and with high cardiovascular risk.
30 patients were enrolled but the preliminary data currently collected concern 10 patients (8 men and 2 women) with an average age of 65.3 years, who were administered Medronys Colesterolo® twice a day for 30 days. The results showed that the treatment significantly improved the lipid profile for total cholesterol.
In particular, preliminary data show a statistically significant reduction in total cholesterol after only 1 month of therapy, while there is no statistically significant change in LDL, HDL and triglyceride cholesterol values.
In conclusion, treatment with Medronys Colesterolo® in patients with chronic renal failure treated with dialysis therapy, who cannot take conventional therapy with statins due to the severity of the renal disease, provides comforting results and a significant clinical advantage, since normalization of total cholesterol allows to reduce the cardiovascular risk in this type of patient.
Further investigations and extension of cases under examination are underway.